Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutamise or Transglutamise C or Transglutamise H or Transglutamise 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) - Overview
Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutamise or Transglutamise C or Transglutamise H or Transglutamise 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutamise or Transglutamise C or Transglutamise H or Transglutamise 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutamise or Transglutamise C or Transglutamise H or Transglutamise 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) - Companies Involved in Therapeutics Development
Catabasis Pharmaceuticals Inc
Zedira GmbH
Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutamise or Transglutamise C or Transglutamise H or Transglutamise 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) - Drug Profiles
CAT-5571 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DN-201782 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ERW-1041E - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZED-1227 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZED-754 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutamise or Transglutamise C or Transglutamise H or Transglutamise 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) - Dormant Products
Protein Glutamine Gamma Glutamyltransferase 2 (Tissue Transglutamise or Transglutamise C or Transglutamise H or Transglutamise 2 or TGase C or TGase H or TGM2 or EC 2.3.2.13) - Product Development Milestones
Featured News & Press Releases
Oct 26, 2017: Catabasis Pharmaceuticals Announces Upcoming Presentation on CAT-5571 as a Potential Treatment for Cystic Fibrosis at the 31st Annual North American Cystic Fibrosis Conference
Jun 08, 2017: Catabasis Pharmaceuticals Presents New Data for CAT-5571 as a Novel Potential Oral Treatment for Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference
Jun 02, 2017: Catabasis Pharmaceuticals to Present CAT-5571, a Novel Activator of Autophagy, as a Potential Treatment for Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference
May 02, 2017: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
Jan 05, 2017: Catabasis Pharmaceuticals Research on CAT-5571, a Novel Activator of Autophagy and Potential Oral Treatment for Cystic Fibrosis, Published in Jourl of Medicil Chemistry
Nov 30, 2016: Zedira receives funding from the German Government for the development of transglutamise inhibitor ZED-1227 for the treatment of diabetic nephropathy
Nov 17, 2016: Catabasis Pharmaceuticals Provides Update on Rare Disease Program CAT-5571 at Investor Day
Oct 27, 2016: Catabasis Pharmaceuticals Presents Positive Data for CAT-5571, a Novel Activator of Autophagy, as a Potential Oral Treatment for Cystic Fibrosis at the 30th Annual North American Cystic Fibrosis Conference
Oct 20, 2016: Catabasis Pharmaceuticals to Present CAT-5571, a Novel Activator of Autophagy, as a Potential Treatment for Cystic Fibrosis at the 30th Annual North American Cystic Fibrosis Conference
Jul 01, 2016: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
Oct 20, 2015: Additiol subsidy funding for clinical development of a celiac disease drug
Mar 02, 2015: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
Mar 19, 2009: Numerate Awarded Phase 1 NIH Grant To Support Design Of New Therapies For Celiac Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019


List of Tables


Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indication, H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Number of Products under Investigation by Universities/Institutes, H1 2019
Products under Investigation by Universities/Institutes, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by Catabasis Pharmaceuticals Inc, H1 2019
Pipeline by Zedira GmbH, H1 2019
Dormant Projects, H1 2019